49 completed, 11 unknown, 8 recruiting, 5 terminated. 45 Phase 2, 23 Phase 3, 9 Phase 1, 6 Phase 4, 3 Not applicable.
Follow romiplostim: new trials by email Literature Review of romiplostim trials Research Report on romiplostim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Amgen | 126 | 2026-08-21 | 2026-09-17 |
| Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents Romiplostim, darbepoetin alfa, Methoxy Polyethylene Glycol-Epoetin Beta - Anemia Associated With Chronic Kidney Disease | Phase 2 | Recruiting | Chinese University of Hong Kong | 12 | 2026-08-11 | 2026-10-02 |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 164 | 2026-08-04 | 2026-10-22 |
| Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. Nplate, NaCl %0.9 - Chirurgical Intervention, Thrombocytopaenia | Phase 2 | Recruiting | Nantes University Hospital | 142 | 2026-07-16 | 2026-10-28 |
| Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP atorvastatin, NAC, and romiplostim - Immune Thrombocytopenic Purpura | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-06-01 | 2026-06-23 |
| Romiplostim for Oral TPO-RA Resistant ITP Romiplostim - Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 60 | 2026-03-15 | 2026-05-28 |
| Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA Romiplostim, Recombinant Human Thrombopoietin - MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 66 | 2026-01-31 | 2026-04-15 |
| UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia Romiplostim, Immunosuppressive therapy (IST) - Aplastic Anemia | Phase 2 | Withdrawn | Anjali Sharathkumar | 2025-04-10 | 2026-10-16 | |
| Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP corticosteroids combined with immunoglobulin and romiplostim - Primary Immune Thrombocytopenia | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 36 | 2024-11-20 | 2025-01-22 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT Romiplostim - Thalassemia in Children | Completed | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | 16 | 2024-09-01 | 2026-07-28 | |
| A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA Romiplostim - Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2024-08-02 | 2024-08-02 |
| Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study Romiplostim - Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 40 | 2024-07-30 | 2024-07-24 |
| Single Arm Romiplostim to Prevent CIT Romiplostim (AMG-531) - Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia | Early Phase 1 | Recruiting | Children's Hospital Medical Center, Cincinnati | 26 | 2024-01-26 | 2026-03-18 |
| Romiplostim in Chemotherapy-Induced Thrombocytopenia Romiplostim - Chemotherapy-induced Thrombocytopenia, Solid Malignancy | Phase 3 | Unknown | Ain Shams University | 30 | 2023-12-17 | 2024-01-11 |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy Romiplostim, Antithymocyte Globulin, Cyclosporine A - Severe Aplastic Anemia (SAA) | Phase 2 | Withdrawn | Amgen | 2023-08-31 | 2023-09-29 | |
| Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA Romiplostim, Ciclosporin - Non Severe Aplastic Anemia | Phase 4 | Unknown | Peking Union Medical College Hospital | 44 | 2023-08-01 | 2023-08-24 |
| Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia GP404141, Nplate - Drug Effect, Safety Issues | Phase 3 | Active not recruiting | Geropharm | 160 | 2023-04-04 | 2024-07-11 |
| Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia romiplostim plus dexamethasone, Dexamethasone - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 129 | 2022-12-02 | 2025-06-17 |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma Lomustine, Romiplostim - First Progression of MGMT Promoter-methylated Glioblastoma | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2022-09-13 | 2023-05-24 |
Showing 20 of 82. Sign in to see all of them.
Thrombocytopenia (34) · Purpura, Thrombocytopenic, Idiopathic (33) · Purpura, Thrombocytopenic (12) · Anemia, Aplastic (10) · Myelodysplastic Syndromes (7) · Lymphoma, Non-Hodgkin (5) · Hematologic Diseases (3) · Hemorrhage (3) · Hodgkin Disease (3) · Jacobs syndrome (3) · Multiple Myeloma (3) · Neoplasms (3) · Purpura (3) · Autoimmune Diseases (2) · Carcinoma, Non-Small-Cell Lung (2)
Amgen (26) · Kyowa Kirin Co., Ltd. (5) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (3) · Peking Union Medical College Hospital (3) · AO GENERIUM (2) · Anjali Sharathkumar (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Geropharm (2) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (2) · GlaxoSmithKline (2) · Kyowa Kirin China Pharmaceutical Co., Ltd. (2) · The First Affiliated Hospital of Soochow University (2) · Ain Shams University (1) · Andres J. M. Ferreri (1)
United States (25) · China (10) · Russia (8) · France (7) · Spain (7) · Canada (6) · Italy (5) · Australia (4) · Germany (4) · Japan (4) · Mexico (4) · Poland (4) · Brazil (3) · Hungary (3) · Switzerland (3)
Oksana A. Markova, MD, MSc (2) · Saroj Vadhan-Raj, MD (2) · Amitabha Mazumder (1) · Anjali A. Sharathkumar, MBBS, MD, MS (1) · Anjali Sharathkumar, MD (1) · Anna Shcherbina, MD, PhD (1) · Bing Han, PhD (1) · Brian Turpin, DO (1) · Bulat Bakirov, MD (1) · Cameron Gaskill, MD (1) · Charlotte Bradbury (1)
PMID 19671919, PMID 18242413, PMID 22494019, PMID 40593138, PMID 19117511, PMID 23190430, PMID 23470153, PMID 23616916, PMID 23753021, PMID 24802773, PMID 25132654, PMID 27103127, PMID 27307776, PMID 28616874, PMID 29659042, PMID 30945320, PMID 31474546, PMID 31545663, PMID 31586022, PMID 34921514, PMID 36409612, PMID 37601010, PMID 37735543, PMID 37740581, PMID 37765023, PMID 40708707
2017 (2), 2009 (1), P30CA016087 (1)